SyntheticMR announced today that version 15 of
their next-generation imaging solution, SyMRI Neuro, has obtained
CE-marking.
LINKÖPING, Sweden,
June 26,
2024 /PRNewswire/ -- SyMRI 15 is a cutting-edge
imaging solution set to transform the medical imaging landscape
with a host of innovative applications integrated into SyMRI's
post-processing suite. In addition to the previously communicated
launch of SyMRI 3D (14), the reinforced solution now include images
that are proven to have the same capability as conventional for
diagnostic purpose and thereby offer even more value from same
sequence.
SyMRI 15 has been clinically proven and validated in a large
multi-center study across several high-profile institutes in
the United States. The results of
the clinical study showed that SyMRI 3D can replace conventional 3D
images, enhancing both efficiency and throughput. This is in
addition to its established capabilities in providing quantitative
values and tissue segmentation. The findings reinforce its
diagnostic accuracy, instilling confidence in SyMRI users to
substitute conventional 3D images with SyMRI T1 and T2 images.
With the introduction of SyMRI 15, we are also unveiling tools
for efficient patient monitoring, alongside providing
contrast-weighted images and quantitative information. This
technique empowers clinicians with deeper insights into patient
health, enabling improved patient care by facilitating a more
comprehensive understanding of pathological changes and treatment
effects over time.
"We are thrilled to announce that Version 15 of our 3D SyMRI
solution is now CE-marked," says Ulrik Harrysson, CEO of
SyntheticMR AB. "This next generation of SyMRI 3D delivers
unparalleled resolution and accuracy in brain imaging, transforming
the field of medical diagnostics."
SyntheticMR has an exclusive agreement with Philips Healthcare
for the distribution of SyMRI 15. This agreement between Philips
and SyntheticMR means that SyMRI 3D will be included in Philips'
global price book and enable Philips to offer the complete package
to their customers.
The CE mark qualification for SyMRI 3D signifies a monumental
stride for SyntheticMR, reaffirming its commitment to transforming
medical imaging on a global level.
This disclosure contains information that SyntheticMR AB is
obliged to make public pursuant to the EU Market Abuse Regulation
(EU nr 596/2014). The information was submitted for publication,
through the agency of the contact person, on 26-06-2024 13:30
CET.
For additional information, please contact Ulrik Harrysson,
CEO, SyntheticMR AB, +46 70 529
2987 ulrik.harrysson@syntheticmr.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/syntheticmr-ab/r/symri-15-by-syntheticmr-obtains-ce-marking,c4006088
The following files are available for download:
|
https://mb.cision.com/Main/11663/4006088/2885585.pdf
|
Release
|
View original
content:https://www.prnewswire.co.uk/news-releases/symri-15-by-syntheticmr-obtains-ce-marking-302183107.html
